Pacylex is an Edmonton-based pre-clinical trial stage pharmaceutical company developing a first-in-class, oral drug to selectively kill various types of cancer cells while leaving normal cells unharmed.
Four major haematological, or blood cancers account for almost 10 per cent of new cancer cases and deaths, including leukemia and lymphoma. There is an urgent need for new and effective treatments, especially for cases that do not respond to currently available therapies. Pacylex is working to bring its new medicine to human clinical studies.
In March of 2021, Pacylex received Health Canada approval for Phase 1 human clinical trials for its anti-cancer drug PCLX-001.
Pacylex is a part of Alberta Innovates’ Accelerating Innovations into CarE (AICE) program.
Pacylex Pharmaceuticals, Cross Cancer Institute, Alberta Health Services